Cyanosis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
===== Ultrasound follow-up ===== | ===== Ultrasound follow-up ===== | ||
* Serial assessment should be guided by the nature and severity of the lesion, presence of heart failure, anticipated timing and mechanism of progression, and the options available for prenatal and postpartum intervention. [14]. | |||
* Assessment should be performed through infancy at 6- to 12-month intervals, and longer if abnormalities are present. | |||
This is also an appropriate time to screen for growth restriction, which may be more prevalent in these fetuses or specific subtypes of congenital heart disease [45-48]. | * At least one follow-up examination early in the third trimester is reasonable in order to look for abnormalities that progressed in severity or may not have been detectable earlier in gestation, and have peripartum clinical implications. | ||
* This is also an appropriate time to screen for growth restriction, which may be more prevalent in these fetuses or specific subtypes of congenital heart disease [45-48]. | |||
All infants with severe PPHN who have been treated with inhaled nitric oxide (iNO) and/or extracorporeal membrane oxygenation (ECMO) should have neurodevelopmental follow-up [15] | * All infants with severe PPHN who have been treated with inhaled nitric oxide (iNO) and/or extracorporeal membrane oxygenation (ECMO) should have neurodevelopmental follow-up [15]. | ||
==References== | ==References== | ||
Revision as of 06:01, 23 March 2018
|
Cyanosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cyanosis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Cyanosis secondary prevention |
|
Risk calculators and risk factors for Cyanosis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Secondary Prevention
Ultrasound follow-up
- Serial assessment should be guided by the nature and severity of the lesion, presence of heart failure, anticipated timing and mechanism of progression, and the options available for prenatal and postpartum intervention. [14].
- Assessment should be performed through infancy at 6- to 12-month intervals, and longer if abnormalities are present.
- At least one follow-up examination early in the third trimester is reasonable in order to look for abnormalities that progressed in severity or may not have been detectable earlier in gestation, and have peripartum clinical implications.
- This is also an appropriate time to screen for growth restriction, which may be more prevalent in these fetuses or specific subtypes of congenital heart disease [45-48].
- All infants with severe PPHN who have been treated with inhaled nitric oxide (iNO) and/or extracorporeal membrane oxygenation (ECMO) should have neurodevelopmental follow-up [15].